IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
By Hong Sun, Pouya Saeedi, S. Karuranga, Moritz Pinkepank, K. Ogurtsova, B. Duncan, C. Stein, A. Basit, J. Chan, J. Mbanya and 10 more. Diabetes Research and Clinical Practice, 2021
8,497 citations recorded by the source corpus.
Aims: To provide global, regional, and country-level estimates of diabetes prevalence and health expenditures for 2021 and projections for 2045. Methods: A total of 219 data sources meeting pre-established quality criteria reporting research conducted between 2005 and 2020 and representing 215 countries and territories were identified. For countries without data meeting quality criteria, estimates were extrapolated from countries with similar economies, ethnicity, geography and language. Logistic regression was used to generate smoothed age-specific diabetes prevalence estimates. Diabetes-related health expenditures were estimated using an attributable fraction method. The 2021 diabetes prevalence estimates were applied to population estimates for 2045 to project future prevalence. Results: The global diabetes prevalence in 20–79 year olds in 2021 was estimated to be 10.5% (536.6 million people), rising to 12.2% (783.2 million) in 2045. Diabetes prevalence was similar in men and women and was highest in those aged 75–79 years. Prevalence (in 2021) was estimated to be higher in urban (12.1%) than rural (8.3%) areas, and in high-income (11.1%) compared to low-income countries (5.5%). The greatest relative increase in the prevalence of diabetes between 2021 and 2045 is expected to occur in middle-income countries (21.1%) compared to high- (12.2%) and low-income (11.9%) countries. Global diabetes-related health expenditures were estimated at 966 billion USD in 2021, and are projected to reach 1,054 billion USD by 2045. Conclusions: Just over half a billion people are living with diabetes worldwide which means that over 10.5% of the world’s adult population now have this condition.
Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Organizational Behavior and Human Resource Management
View Paper: https://www.semanticscholar.org/paper/490cc05b148919a57472ad08bd650bf3cd9842e5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 (2023, neutral): “47 A high diabetes burden in LMICs is also related to economic and sociopolitical challenges, including limited health spending on diabetes 10 and inadequate or incomplete coverage for pharmacological treatment.”
- Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024, neutral): “19,20 Our approach to defining diabetes is consistent with current clinical guidelines and practice, 6–9 , 21– 24 and avoids 32 For example, our estimated prevalence for India is similar to that of the ICMR-INDIAB surveys 26 when both blood glucose and HbA 1c are used, which is higher than…”
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (2022, background): “5 million people, with 540 million people affected (340,341).”
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022, neutral): “5 million people, with 540 million people affected [340, 341].”